Serum NRG1 levels were significantly reduced across all patient groups (RRMS, SPMS, MS, and NMO) compared to healthy controls, with the most significant decrease observed in NMO patients (Fig. 1A). The gene discussed is NRG1; the disease is myeloid sarcoma.